The US Supreme Court has ruled against a legal challenge that sought to restrict the availability of mifepristone, an abortion medication, by mail. This decision means that existing regulations, which permit remote prescribing and postal delivery of the drug, will remain in effect across the United States.
The legal action was initiated by the state of Louisiana, which aimed to curtail the regulatory agency's rules concerning the remote prescription of mifepristone. Had the challenge been successful, it could have significantly impacted access to abortion services for many American women, particularly those in rural areas or states with stricter abortion laws.
Mifepristone is one of two medications used in a medical abortion, typically taken with misoprostol. It works by blocking the hormone progesterone, which is necessary for a pregnancy to continue. The drug has been approved for use in the US by the Food and Drug Administration (FDA) since 2000 and has a well-established safety record.
The ruling by the Supreme Court effectively upholds the FDA's long-standing authority to regulate drug access and safety. This outcome provides clarity for healthcare providers and patients regarding the continued availability of this medication, which accounts for more than half of all abortions in the US.
For UK readers, it is important to note that abortion provision is governed by different legal and regulatory frameworks. In the UK, medical abortions, including those using mifepristone, are available through NHS services and approved providers, subject to the provisions of the Abortion Act 1967. During the COVID-19 pandemic, temporary measures were introduced in the UK to allow for at-home early medical abortion after a remote consultation, which have since been made permanent in England and Wales.